Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

EU HTA Publication Digest: Implementation of the EU's Health Technology Assessment regulation: where does existing methods guidance require concretization and what are the relevant methodological options?

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. 

In a recent publication, Goetz et al. examined where EUnetHTA guidance documents require further methodological clarity in light of the upcoming EU HTA regulation. Through a systematic document review and structured stakeholder discussions conducted in Austria, the authors identified 32 key areas in need of refinement primarily related to evidence synthesis and eligibility criteria. Drawing on established HTA and evidence synthesis handbooks, the authors proposed concrete methodological options, offering actionable insights to support implementation across EU member states.

Access the full-text article here.